Clinical Trial – Genetic Susceptibility to Bladder Cancer – Bladder Cancer

This clinical research study will identify biologic and lifestyle factors which increase a person’s risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

 

Study Type  : Observational
Estimated Enrollment  : 4500 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach
Actual Study Start Date  : February 10, 1998
Estimated Primary Completion Date  : August 2019
Estimated Study Completion Date  : August 2019

 

Contacts
Contact: Xifeng Wu, MD 713-792-3020 xwu@mdanderson.org
Contact: Tao T Le, Program Director, Epidemiology tle@mdanderson.org

ClinicalTrials.gov Identifier: NCT00848289

Locations
United States, Texas
Baylor College of Medicine Terminated
Houston, Texas, United States, 77030
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Xifeng Wu, MD 713-792-3020 xwu@mdanderson.org

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.